No profile data available.
Dyne Therapeutics, Inc. (DYN) is a healthcare company in the brain and nerve treatment drugs industry, based in Waltham, United States, with about 289 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$446.21 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $3.11 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
Dyne Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$3.11 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Xenon Pharmaceuticals Inc. (XENE), Acadia Pharmaceuticals Inc. (ACAD), Denali Therapeutics Inc. (DNLI), Supernus Pharmaceuticals, Inc. (SUPN).